Completed NA INTERVENTIONAL 2-arm NCT01034540

Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Acid Ethyl Esters on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

Sponsor: GlaxoSmithKline

Conditions Hypertriglyceridemia

Interventions POM3 Placebo

Updated 8 times since 2017 Last updated: May 1, 2024 Started: Mar 31, 2010 Primary completion: Dec 31, 2010 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01034540, this NA trial focuses on Hypertriglyceridemia and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2024 — Jul 2024 [monthly]

Completed NA
Dec 2021 — Jun 2024 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Provident Clinical Research

Data source: Provident Clinical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Addison, United States